Optimal treatment of locally advanced prostate cancer

World Journal of Urology

Volumn 25, Issue 2, 2007, Pages 169-176

  Wirth, Manfred P ^a   Hakenberg, Oliver W ^b   Froehner, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Conservative therapy; Hormonal therapy; Locally advanced; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34047178897     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0158-7     Document Type: Article

References (81)

1. Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM (2006) Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 98:335-340
2. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG et al (2001) Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer 91:2302-2314
3. Ward JF, Slezak JM, Blute ML, Bergstrahl EJ, Zincke H (2005) Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95:751-756
4. Karlsdottir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O (2004) Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71:43-53
5. Aus G, Abbou CC, Heidenreich A, Schmid HP, van Poppel H, Wolff J et al (2005) EAU guidelines on prostate cancer. Eur Urol 48:546-551
6. Isorna Martinez de la Riva S, Belon Lopez-Tomasety J, Marrero Dominguez R, Alvarez Cruz E, Santamaria Blanco P (2004) Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 57(7):679-692
7. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 32(4):385-390
8. Amling CL, Leibovich BC, Lerner SE, Bergstrahl EJ, Blute ML, Myers RP et al (1997) Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 15(4):215-221
9. Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E et al (2006) Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol [Epub ahead of print]
10. Hakenberg OW, Froehner M, Wirth MP (2006) Treatment of locally advanced prostate cancer - the case for radical prostatectomy. Urol Int 77:193-199
11. Meraney AM, Haese A, Palisaar J, Graefen M, Steuber T, Huland H et al (2005) Surgical management of prostate cancer: Advances based on a rational approach to the data. Eur J Cancer 41:888-907
12. Brassell SA, Rosner IL, McLeod DG (2005) Update on magneteic resonance imaging, ProstaScint and novel imaging in prostate cancer. Curr Opin Urol 15:163-166
13. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T (2005) 11C-Choline Positron emission tomography in prostate cancer: Primary staging and recurrent site staging. Urol Int 74(2):214-220
14. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445-1451
15. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-848
16. Wolff JM, Zimny M, Burchers H, Wildberger J, Buell U, Jakse G (1998) Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 33:376-381
17. Puppo P, Perachino M (1997) Clinical stage, prostate-specific antigen and Gleason grade to predict extracapsular disease or nodal metastasis in men with newly diagnosed, previously untreated prostate cancer. Eur Urol 32:273-279
18. Sands ME, Zagars GK, Pollack A, von Eschenbach AC (1994) Serum prostate-specific antigen, clinical stage, pathological grade and the incidence of nodal metastases in prostate cancer. Urology 44:215-220
19. Neulander EZ, Soloway MS (2003) Failure after radical prostatectomy. Urology 61:30-36
20. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565
21. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523
22. Zincke H, Fleming TR, Furlow WL, Myers RP, Utz D (1981) Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate. Cancer 47:1901-1910
23. Lerner SE, Blute ML, Zincke H (1995) Extended experience with radical prostatectomy for clinical stage T3 prostate cancer. Outcome and contemporary morbidity. J Urol 154:1447-1452
24. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H (2007) Outcome of surgery for clinical unilateral T3a prostate cancer: A single-institution experience. Eur Urol 51:121-129
25. Cadeddu JA, Partin AW, Epstein JI, Walsh PC (1997) Stage D1 (T1-3,N1-3,M0) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50:251-255
26. van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients in locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160(4):1392-1397
27. van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, van de Voorde W, Baert L (2000) Radical prostatectomy can provide cure for well selected clinical stage T3 prostate cancer. Eur Urol 38:372-379
28. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA (2006) Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176:564-568
29. Frohmüller HGW, Theiss M, Manseck A, Wirth MP (1995) Survival and quality of life of patients with stage D1 (T1-3,pN1-2,M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 27:202-206
30. Wiegel T, Bottke D, Willich N, Piechota H, Souchon R, Stoeckle M et al (2005) Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95). Proc ASCO #4513
31. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS (1995) The efficacy of post-prostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 32:317
32. Bolla M (2003) Treatment of localized or locally advanced prostate cancer: The clinical use of radiotherapy. EAU Update Ser 1:23-31
33. Davis BJ, Pisansky TM, Leibovich BC (2003) Adjuvant external radiation therapy following RP for node-negative prostate cancer. Curr Opin Urol 13:117-119
34. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K et al (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865-1870
35. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP et al (2006) Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97:247-254
36. Steinberg GD, Epstein JI, Piantadosi S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974-1987. J Urol 144:1425-1432
37. Frazier HA, Roberston JE, Paulson DF (1994) Does radical prostatectomy in the presence of positive lymph nodes enhance survival? World J Urol 12:308-312
38. deKernion JB, Huang MY, Kaufmann JJ, Smith RB (1985) Result of treatment of patients with stage D1 prostatic carcinoma. Urology 26:446-451
39. Golimbu M, Provet J, Al-Akari S, Morales P (1987) Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology 30:427-435
40. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91:66-73
41. Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849-854
42. Roach M, Lu J, Pilepich MV, Ashell SO, Mohiuddin M, Terry R et al (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609-615
43. Crook JM, Perry GA, Robertson S, Esche BA (1995) Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 45:624-631
44. Zietman AL, Westgeest JC, Shipley WU (1997) Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol 15:230-238
45. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106
46. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300
47. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Schultheiss TE (1999) Survival advantage for prostate cancer patients treated with-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5(3):152-158
48. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach A, Antolak JA et al (2000) Preliminary results of a randomised dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911
49. Yoshioka Y, Konishi K, Oh RJ, Sumida I, Yamazaki H, Nakamura S et al (2006) High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 80:62-68
50. Adolfsson J, Steineck G, Hedlund P (1999) Deferred treatment of locally advanced nonmetastatic prostate cancer: A long-term follow-up. J Urol 161:505-508
51. Lundgren R, Nordle Ö, Josefsson K (1995) South Sweden Prostate Cancer Study Group. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in non-metastatic prostate cancer. A randomized multicenter study with 15 years follow-up. J Urol 153:1580-1586
52. The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 79:235-246
53. Iversen P, Tyrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TLJ et al (2000) Bicalutamide ('Casodex') 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years' follow-up. J Urol 164:1579-1582
54. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K et al (2004) Bicalutamide ('Casodex') 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: Update d analysis at a median 5.4 years' follow-up. J Urol 172:1865-1870
55. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr et al (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116
56. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M et al (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year followup of a randomized controlled trial. BJU Int 90:561-566
57. Klotz LH, Goldenberg SL, Jewett MASFY, Nam R, Barkin J, Chin J et al (2003) Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170:791-794
58. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR et al (2003) Finasteride and flutamide therapy in patients with advanced prostate cancer: Response to subsequent castration and long-term follow-up. Urology 62:99-104
59. Khan MA, Partin AW (2003) Management of high-risk populations with locally advanced prostate cancer. Oncologist 8:259-269
60. Miyake H, Sakai I, Harada KI, Takechi Y, Hara I, Eto H (2005) Prognostic significance of the tumor volume in radical prostatectomy specimens after neoadjuvant hormonal therapy. Urol Int 74(1):27-31
61. Pilepich MV, Winter K, John MJ et al (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252
62. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11:5233-5240
63. Berger AP, Niescher M, Fischer-Colbrie R, Pelzer A, Bartsch G, Horninger W (2004) Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high grade localized prostate cancers. Urol Int 73(2):110-112
64. Helpap B, Kloppel G (2002) Neuroendocrine carcinomas of the prostate and urinary bladder: A diagnostic and therapeutic challenge. Virchows Arch 440:241-248
65. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB et al (1997) Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy - report of RTOG protocol 85-31. J Clin Oncol 15:1013-1021
66. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B et al (2003) Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of phase III RTOG trial 85-31. Int J Radiat Oncol Biol Phys 57(Suppl. 2):S172-S173 [abstract]
67. Yamanaka H, Ito K, Naito S, Tsukamoto T, Usami M, Fujimoto H et al (2005) Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 63:56-64
68. Zincke H, Bergstralh EJ, Larson-Keller JJ, Farrow GM, Myers RP, Lieber MM et al (1992) Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 70:311-323
69. Seay TM, Blute ML, Zincke H (1998) Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 159:357-364
70. Zincke H, Lau W, Bergstralh, Blute ML (2001) Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 166:2208-2215
71. Messing EM, Manola J, Saqrosdy M et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788
72. Schröder FH, Kurth KH, Fossa SD, Hoekstra WJ, Karthaus HM, Dubois M et al (2004) Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study. J Urol 172:923-927
73. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H et al (2004) Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45:267-270
74. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE et al (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937-946
75. Granfors T, Modig H, Damber JE, Tomic R (2006) Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 176:544-547
76. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21:3972-3978
77. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827
78. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J et al (2001) Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 58:146-151
79. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479
80. Prayer-Galetti T, Zattoni F, Capizzi A, Dal Moro F, Pagano F (2000) On behalf of the study group. Disease free survival in patients with pathological "C stage" prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 38(Suppl 4):504
81. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J WD, Hetherington J et al (2005) Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 8:194-200